Evaluation of erdosteine effect on systemic inflamation biomarkers during COPD exacerbations - ERD/inflammation/COPD

• Conditions: COPD exacerbation; MedDRA version: 9.1Level: SOCClassification code 10038738

• Registration Number: EUCTR2008-008529-32-IT
• Lead Sponsor: .O.PNEUMOLOGIA- AZ. USL1 DI MASSA E CARRARA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01-05
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

hospitalized patiens with COPD exacerbation
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

severe systemic clinic complications

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: evaluation of erdosteine activity on systemic inflammation during COPD exacerbation;Secondary Objective: evaluation of erdosteine activity on inflammation biomarkers;Primary end point(s): erdosteine activity on serum biomarkers of inflammation